









Markets
/
Stocks
/
nasdaq-bbnx
/

Beta Bionics Inc

BBNX

13.080USD

-0.160-1.21%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

575.41MMarket Cap

LossP/E TTM



Beta Bionics Inc

13.080

-0.160-1.21%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Beta Bionics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Beta Bionics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.82.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beta Bionics Inc's Score

Industry at a Glance

Industry Ranking

55 / 205

Overall Ranking

158 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Beta Bionics Inc Highlights

StrengthsRisks

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 36282.12% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 65.12M.

Overvalued

The company’s latest PE is -6.73, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 48.60M shares, increasing 0.09% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.22M shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

28.818

Target Price

+117.66%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Beta Bionics Inc is 7.42, ranking 86 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 27.25M, representing a year-over-year increase of 63.14%, while its net profit experienced a year-over-year increase of 45.94%.

Score

Industry at a Glance

Previous score

7.42

Change



Financials

8.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.19

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.31

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Beta Bionics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Beta Bionics Inc is 7.16, ranking 120 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -6.73, which is -0.86% below the recent high of -6.67 and -176.80% above the recent low of -18.64.

Score

Industry at a Glance

Previous score

7.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Beta Bionics Inc is 8.18, ranking 53 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 32.00, with a high of 35.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

8.18

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

28.818

Target Price

+117.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Beta Bionics Inc

BBNX

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Beta Bionics Inc is 6.52, ranking 135 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 20.37 and the support level at 9.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.151

Neutral

RSI(14)

23.193

Sell

STOCH(KDJ)(9,3,3)

8.739

Oversold

ATR(14)

1.100

Low Volatility

CCI(14)

-107.336

Sell

Williams %R

97.064

Oversold

TRIX(12,20)

-2.682

Sell

StochRSI(14)

38.579

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

13.714

Sell

MA10

14.236

Sell

MA20

15.903

Sell

MA50

24.507

Sell

MA100

24.226

Sell

MA200

20.111

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Beta Bionics Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 106.14%, representing a quarter-over-quarter decrease of 0.01%. The largest institutional shareholder is The Vanguard, holding a total of 2.22M shares, representing 5.04% of shares outstanding, with 208.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Eventide Asset Management, LLC

4.96M

+0.50%

Farallon Capital Management, L.L.C.

4.31M

+2.62%

Wellington Management Company, LLP

3.90M

Soleus Capital Management, L.P.

3.87M

+1.31%

Sands Capital Ventures LLC

3.57M

Morgan Stanley & Co. LLC

3.40M

+16.39%

RTW Investments L.P.

3.30M

BlackRock Institutional Trust Company, N.A.

2.58M

+225.18%

The Vanguard Group, Inc.

Star Investors

2.22M

+213.48%

Omega Fund Management, LLC

1.92M

-3.43%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Beta Bionics Inc is 4.69, ranking 98 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.